| Phase 3 |
| NCT06744504 |
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid… |
AML |
Recruiting |
| NCT02339740 |
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic… |
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA |
Active, Not Recruiting |
| NCT07486479 |
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and… |
Acute Myeloid Leukemia (AML) |
Not Yet Recruiting |
| Phase 2 |
| NCT07228273 |
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for… |
Acute Myeloid Leukemia |
Recruiting |
| NCT07046078 |
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body… |
Acute Leukemia of Ambiguous Lineage |
Recruiting |
| NCT00801489 |
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin… |
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 |
Recruiting |
| NCT02115295 |
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute… |
Acute Biphenotypic Leukemia |
Recruiting |
| NCT03589729 |
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in… |
Acute Myeloid Leukemia |
Recruiting |
| NCT03164057 |
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia |
Acute Myeloid Leukemia |
Active, Not Recruiting |
| NCT04801797 |
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML |
Acute Myeloid Leukemia |
Active, Not Recruiting |
| NCT06744556 |
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML |
AML |
Active, Not Recruiting |
| NCT04214249 |
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual… |
Acute Myeloid Leukemia |
Active, Not Recruiting |
| Phase 1/2 |
| NCT03214562 |
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or… |
High Risk Myelodysplastic Syndrome |
Recruiting |
| NCT06928662 |
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation… |
Acute Myeloid Leukemia |
Recruiting |
| NCT03330821 |
Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia |
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome |
Active, Not Recruiting |
| NCT07604233 |
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML |
Myeloid Leukemia |
Not Yet Recruiting |
| Phase 1 |
| NCT04375631 |
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell… |
Recurrent Acute Myeloid Leukemia |
Recruiting |
| NCT06001788 |
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory… |
AML |
Recruiting |
| NCT06034470 |
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of… |
Acute Myeloid Leukemia |
Active, Not Recruiting |
| NCT02632708 |
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy… |
Newly Diagnosed Acute Myeloid Leukemia (AML) |
Active, Not Recruiting |
| NCT04190550 |
Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments… |
Acute Myeloid Leukemia |
Active, Not Recruiting |